Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stuttgart - Delayed Quote EUR

uniQure NV (UQ1.SG)

12.40
-0.16
(-1.31%)
At close: April 25 at 9:46:53 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UQ1.SG

Recent News: UQ1.SG

View More
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
Zacks 6 days ago
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy

FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
Pharmaceutical Technology 6 days ago
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
GlobeNewswire 10 days ago
uniQure Full Year 2024 Earnings: Misses Expectations

uniQure Full Year 2024 Earnings: Misses Expectations
Simply Wall St. last month
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Zacks last month
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
GlobeNewswire last month
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
Simply Wall St. 2 months ago
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
Benzinga 2 months ago
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
PR Newswire 2 months ago
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
GlobeNewswire 2 months ago
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
GlobeNewswire 2 months ago
View More

Related Tickers

0NZU.IL Zealand Pharma A/S
425.44
+0.78%
 
ADXN Addex Therapeutics Ltd
8.16
+11.78%
 
RNA Avidity Biosciences, Inc.
30.84
-0.29%
 
MRNA Moderna, Inc.
27.22
-0.62%